Ozmosi | ASKC-200 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

ASKC-200

Alternative Names: ASKC-200, ASKC 200, ASKC200
Clinical Status: Active
Latest Update: 2024-09-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TRPV1 Modulator

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: PropellaTherapeutics,Inc./Jiangsu Aosaikang Pharmaceutical Co., Ltd./FrontageLaboratories,Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASKC-200

Countries in Clinic: China

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Osteoarthritis, Knee

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06614608

ASKC200

P1

Not yet recruiting

Osteoarthritis, Knee

2025-04-01

2024-09-27

CTR20243377

CTR20243377

P1

Active, not recruiting

Osteoarthritis, Knee

None

2025-11-09

Start Date|Treatments|Trial Status

CTR20253713

CTR20253713

P2

Active, not recruiting

Osteoarthritis, Knee

None

2026-04-28

Treatments|Trial Status

Recent News Events

Date

Type

Title